Thank you for being a Global Market News subscriber.
Today’s Top Stories:
🤬
Hunter Biden’s $LAPTOP Meme Coin Collapsed in Minutes. Here’s Why Most Meme Coin Buyers Lose
Hunter Biden’s meme coin exploded higher and then collapsed almost immediately. What happened next shows why ordinary investors are often playing a very different game from the people launching and trading meme coins early.
💡Sponsor Spotlight
The Real Power of FDA Breakthrough Designation
The FDA doesn't grant Breakthrough Device Designation easily. It’s reserved for technologies with the potential to tackle life-threatening conditions, granting prioritized regulatory review.
Eliaz Therapeutics has earned this title for XGal-3®, an investigational sepsis device being advanced toward human clinical trials next year.
This device targets Galectin-3, a protein that’s a key driver in the sepsis immune response, removing it directly from the bloodstream before organ failure sets in. Sepsis is a $100B/year problem, and there is currently no FDA-approved therapy that targets the cause. Not yet, at least.
Eliaz Therapeutics has 75+ patents across 30+ countries and a global collaboration with a world leader in medical technology, Terumo BCT.
And right now, you have the opportunity to back this technology before it potentially reaches the market.
This is a paid advertisement for Eliaz Therapeutics Inc.'s Regulation CF offering. Please read the offering circular at http://investcf.eliaztherapeutics.com/
⚠️
AI Leaders Warn Their Race Could End in Human Extinction. Now They Want to Slow Down
The people racing to build the most powerful AI systems are now openly warning that they may be moving too fast. Their concern is no longer just job losses or misinformation. It is whether humanity can stay in control at all.
💡Sponsor Spotlight
Primary care physicians can miss up to 46% of skin cancers. This FDA-cleared device is changing that.
Skin cancer is highly survivable when caught early, but for decades primary care doctors have largely relied on visual exams to decide whether a suspicious lesion should be referred to a dermatologist.
DermaSensor has developed the first and only FDA-cleared automated skin cancer detection device for primary care physicians, giving doctors an objective risk result in seconds.
The technology is already gaining traction:
40,000+ lesions scanned to date
10 U.S. health systems and hundreds of practices as customers
Contracted revenue tripled in 2025
Class IIb CE Mark secured for European expansion
$8B+ U.S. and European market
DermaSensor has already raised $20 million from investors and is now giving individual investors an opportunity to participate alongside its institutional backers.
Early-bird investment terms are still available, but the remaining allocation is limited.
Want to advertise in Global Market News?
If your company is interested in reaching an audience of engaged and informed investors.
Know what you own, and know why you own it.
-Peter Lynch
You are receiving this email because you opted in to receive updates from Global Market News. This newsletter may contain sponsored content or advertisements. Information provided is for informational purposes only and should not be considered financial or investment advice. Always consult a financial advisor before making investment decisions.